Ipsen SA

Ipsen S.A. publishes its 2022 Universal registration document

06 Apr 2023 13:04:01 By Nasdaq GlobeNewswire

Ipsen receives new FDA PDUFA date for investigational palovarotene for the treatment of people with FOP

16 Mar 2023 14:02:10 By Nasdaq GlobeNewswire

Ipsen SA - Monthly information relative to the total number of voting rights and shares composing the share capital

10 Mar 2023 12:00:00 By Nasdaq GlobeNewswire

Ipsen completes acquisition of Albireo, expanding the scope of its Rare Disease portfolio

02 Mar 2023 14:13:06 By Nasdaq GlobeNewswire

Ipsen extends expiration date of tender offer for Albireo Pharma, Inc. to 1 March 2023

22 Feb 2023 01:00:00 By Nasdaq GlobeNewswire

Ipsen, Université de Montréal and IRICoR broaden existing oncology partnership, with an exclusive license agreement and two new discovery-stage programs

15 Feb 2023 01:00:00 By Nasdaq GlobeNewswire

Cabometyx® in combination with nivolumab shows durable survival benefits at over three-years’ follow-up in first-line advanced renal cell carcinoma

13 Feb 2023 17:00:00 By Nasdaq GlobeNewswire

IPSEN: Monthly information relative to the total number of voting rights and shares composing the share capital

10 Feb 2023 12:00:00 By Nasdaq GlobeNewswire

Ipsen presents strong full-year 2022 results and guidance for 2023

09 Feb 2023 01:00:02 By Nasdaq GlobeNewswire